Gilead inks pact on experimental RSV treatment

Gilead is throwing its considerable weight behind an RSV drug program now underway at MicroDose Therapeutx. Gilead will pay an undisclosed upfront and bankroll research work on MDT-637, an inhalable small molecule antiviral fusion inhibitor, through Phase IIa, when it will have to decide whether or not to pick up an option to take full responsibility for the treatment. "This strategic collaboration is a significant milestone in MicroDose's vision to develop first-in-class therapies for major unmet medical needs," said Anand Gumaste, the CEO of MicroDose. "Given Gilead's scientific and clinical expertise in virology, this partnership provides a strong validation of the potential for MDT-637 to become an important therapeutic advance for those affected by RSV infection." Gilead release